Molecular mechanism of SLC5A8 inactivation in breast cancer

Molecular and Cellular Biology

Volumn 33, Issue 19, 2013, Pages 3920-3935

  Elangovan, Selvakumar ^a,c   Pathania, Rajneesh ^a   Ramachandran, Sabarish ^a   Ananth, Sudha ^a   Padia, Ravi N ^a   Srinivas, Sonne R ^a   Babu, Ellappan ^a   Hawthorn, Lesleyann ^a   Schoenlein, Patricia V ^a   Boettger, Thomas ^b   Smith, Sylvia B ^a   Prasad, Puttur D ^a   Ganapathy, Vadivel ^a   Thangaraju, Muthusamy ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c KIIT UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; PROTEIN; PROTEIN SLC5A8; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; DNA METHYLATION; GENE EXPRESSION; GENE INACTIVATION; GENE LOSS; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE MAMMARY TUMOR ONCOVIRUS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; BREAST NEOPLASMS; CARCINOGENESIS; CATION TRANSPORT PROTEINS; CELL LINE; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; IMMUNOBLOTTING; MALE; MCF-7 CELLS; MICE; MICE, KNOCKOUT; MICE, NUDE; MICE, TRANSGENIC; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84886790779     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01702-12     Document Type: Article

References (61)

1. +-monocarboxylate cotransporter. J. Physiol. 557:719-731.
2. +-coupled transporter for short-chain fatty acids. J. Biol. Chem. 279: 13293-13296.
3. +-coupled transport of lactate. J. Biol. Chem. 279:44522-44532.
4. +-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J. Neurochem. 98:279-288.
5. Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V. 2005. Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem. J. 388:309-316.
6. Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, Willis J, Willson JK, Plass C, Markowitz SD. 2003. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc. Natl. Acad. Sci. U. S. A. 100:8412-8417.
7. Ganapathy V, Thangaraju M, Gopal E, Itagaki S, Miyauchi S, Prasad PD. 2008. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 10:193-199.
8. Ganapathy V, Thangaraju M, Prasad PD. 2009. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 121:29-40.
9. Gupta N, Martin PM, Prasad PD, Ganapathy V. 2006. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci. 78:2419-2425.
10. Davie JR. 2003. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 133(Suppl. 7):2485S-2493S.
11. Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD, Sterneck E, Ganapathy V. 2006. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res. 66:11560-11564.
12. Thangaraju M, Cresci G, Itagaki S, Mellinger J, Browning DD, Berger FG, Prasad PD, Ganapathy V. 2008. Sodium-coupled transport of the short-chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. J. Gastrointest. Surg. 12:1773-1782.
13. Thangaraju M, Carswell KN, Prasad PD, Ganapathy V. 2009. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem. J. 417:379-389.
14. Insinga A, Monestrioli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG. 2005. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11:71-76.
15. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. 2004. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23:6261-6271.
16. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, Altucci L. 2005. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11:77-84.
17. Zhao Y, Tan J, Zhang L, Jiang X, Liu ET, Yu Q. 2005. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc. Natl. Acad. Sci. U. S. A. 102:16090-16095.
18. Gopal E, Miyauchi S, Martin PM, Ananth S, Roon P, Smith SB, Ganapathy V. 2007. Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract. Pharm. Res. 24:575-584.
19. Manning TS, Gibson GR. 2004. Microbial-gut interactions in health and disease. Prebiotics. Best Pract. Res. Clin. Gastroenterol. 18:287-298.
20. Thangaraju M, Ananth S, Martin PM, Roon P, Smith SB, Sterneck E, Prasad PE, Ganapathy V. 2006. c/ebpdelta null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney. J. Biol. Chem. 281: 26769-26773.
21. Belinsky SA, Nikula KJ, Baylin SB, Issa J-P. 1996. Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc. Natl. Acad. Sci. U. S. A. 93:4045-4050.
22. El-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR, Baylin SB. 1991. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc. Natl. Acad. Sci. U. S. A. 88:3470-3474.
23. Jones PA, Baylin SB. 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3:415-428.
24. Kautiainen TL, Jones PA. 1986. DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture. J. Biol. Chem. 261:1594-1598.
25. Jones PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128:683-692.
26. Kouzarides T. 2007. Chromatin modifications and their function. Cell 128:693-705.
27. Li E, Bestor TH, Jaenisch R. 1992. Targeted mutation of the DNA methyltransferases gene results in embryonic lethality. Cell 69:915-926.
28. Szyf M. 1991. DNA methylation patterns: an additional level of information? Biochem. Cell Biol. 69:764-767.
29. Wu J, Issa JP, Herman J, Bassett DE, Jr, Nelkin BD, Baylin SB. 1993. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. Proc. Natl. Acad. Sci. U. S. A. 90:8891-8895.
30. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, Weinberg RA, Jaenisch R. 1995. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81:197-205.
31. Bigey P, Ramchandani S, Theberg JM, Araujo FD, Szyf M. 2000. Transcriptional regulation of the humanDNAmethyltransferase (dnmt1) gene. Gene 242:407-418.
32. Detich N, Ramchandani S, Szyf M. 2001. A conserved 3=-untranslated element mediates growth regulation of DNA methyltransferase 1 and inhibits its transforming activity. J. Biol. Chem. 276:24881-24890.
33. MacLeod AR, Rouleau J, Szyf M. 1995. Regulation of DNA methylation by the Ras signaling pathway. J. Biol. Chem. 70:11327-11337.
34. Slack A, Cervoni N, Pinard M, Szyf M. 1999. DNA methyltransferase is a downstream effector of cellular transformation triggered by simian virus 40 large T antigen. J. Biol. Chem. 274:10105-10112.
35. Rouleau J, Macleod AR, Szyf M. 1995. Regulation of the DNA methyltransferase by the Ras-AP-1 signaling pathway. J. Biol. Chem. 270:1595-1601.
36. Bakin AV, Curran T. 1999. Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science 283:387-390.
37. Hand PH, Vilasi V, Thor A, Ohuchi N, Schlom J. 1987. Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas. J. Natl. Cancer Inst. 79:59-65.
38. Spandidos DA, Agnantis NJ. 1984. Human malignant tumors of the breast, as compared to their respective normal tissue, have elevated expression of the Harvey ras oncogene. Anticancer Res. 4:269-272.
39. Ohuchi N, Thor A, Page DL, Hand PH, Halter SA, Schlom J. 1986. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. Cancer Res. 46:2511-2519.
40. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. 1996. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am. J. Pathol. 148:313-319.
41. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH, Miller FR. 2001. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res. Treat. 65:101-110.
42. Frank H, Groger N, Diener M, Becker C, Braun T, Boettger T. 2008. Lactaturia and loss of sodium-dependent lactate uptake in the colon of SLC5A8-deficient mice. J. Biol. Chem. 283:24729-24737.
43. Yang G, Thompson JA, Fang B, Liu J. 2003. Silencing of H-ras gene expression by retrovirus-mediated siRNA decrease transformation efficiently and tumor growth in a model of human ovarian cancer. Oncogene 22:5694-5701.
44. National Institutes of Health. 1985. Principles of laboratory animal care. National Institutes of Health publication 85-23. National Institutes of Health, Bethesda, MD.
45. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakfield LM. 2003. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J. Clin. Invest. 112:1116-1124.
46. Houghton J, Morozov A, Smirnova I, Wang TC. 2007. Stem cells and cancer. Semin. Cancer Biol. 17:191-203.
47. Passegue E. 2006. Cancer biology: a game of subversion. Nature 442:754-755.
48. Schuebel K, Chen W, Baylin SB. 2006. CIMPle origin for promoter hypermethylation in colorectal cancer? Nat. Genet. 38:738-740.
49. Dandekar S, Sukumar S, Zarbl H, Young LJ, Cardiff RD. 1986. Specific activation of the cellular Harvey-ras oncogene in dimethylbenzanthracene-induced mouse mammary tumors. Mol. Cell. Biol. 6:4104-4108.
50. Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D, Barbacid M. 1985. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 315:382-385.
51. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, Hutchins AW, Gultekin Y, Peterson TR, Carette JE, Brummelkamp TR, Clish CB, Sabatini DM. 2013. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat. Genet. 45:104-108.
52. Bardeesy N, DePinho RA. 2002. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2:897-909.
53. Bos JL. 1989. Ras oncogenes in human cancer: a review. Cancer Res. 49:4682-4689.
54. De Biasi F, Del Sal G, Hand PH. 1989. Evidence of enhancement of the ras oncogene protein product (p21) in a spectrum of human tumors. Int. J. Cancer 43:431-435.
55. Lund P, Weisshaupt K, Mikesha T, Jammas D, Chen X, Kuban RJ, Ungethum U, Krapfenbauer U, Herzel HP, Schafer R. 2006. Oncogenic H-Ras suppresses clusterin expression through promoter hypermethylation. Oncogene 25:4890-4903.
56. Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J, Borson-Chazot F, Dante R, Rousset B. 2005. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 90:3028-3035.
57. Baccarini M. 2002. An old kinase on a new path: Raf and apoptosis. Cell Death Differ. 9:783-785.
58. Peyssonnaux C, Eychene A. 2001. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell 93:53-62.
59. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-954.
60. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. 2002. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934.
61. Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, Kambara T, MacPhee DG, Young J, Leggett BA, Jass JR, Tanaka N, Matsubara N. 2004. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J. Clin. Oncol. 22:4584-4594.